The Life Sciences IPOs & Capital Markets team advised the underwriters, led by Jefferies LLC, SVB Leerink LLC and Piper Sandler & Co., for the offering of Aclaris Therapeutics, Inc.’s public offering of 7,042,254 shares of its common stock at a price to the public of $17.75 per share. In addition, Aclaris granted to the underwriters a 30-day option to purchase up to 1,056,338 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris were approximately $143.75 million, before deducting underwriting discounts and commissions and offering expenses, including the exercise of the underwriters’ option. The offering closed on June 14, 2021.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options.
The Goodwin team was Della Fok (Corporate), Alexander Varond, and Olivia Uitto (IP).
For more details, read the press release.